Slide 1: resTORbio and Adicet Bio Merger
resTORbio and Adicet Bio Merger April 29, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the expected structure, timing and completion of the proposed merger transaction, futur
Slide 3: Regulation M-A Legend
Regulation M-A Legend Important Additional Information About the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving resTORbio, Inc. (“resTORbio”) and Adicet Bio, Inc. (“Adicet”) and may be deemed to be solicitation material in respect of the
Slide 4: Deal Rationale
Deal Rationale Potential Best-In-Class Allogeneic CAR-T Cell Therapy with Significant Commercial Opportunity First Mover Advantage in the Field of Gamma-Delta CAR-T Cell Therapy Differentiated and Innovative Gamma Delta CAR-T Cell Pipeline Proprietary Intracellular Tumor-Selective Targeting Platform
Slide 5: resTORbio/Adicet Bio Merger
resTORbio/Adicet Bio Merger Close expected 2H 2020 New company expected to be listed on NASDAQ (ticker TBD) Board of Directors expected to include five designated by Adicet + one from resTORbio + CEO On a pro forma basis, Adicet equityholders are expected to own approximately 75% of the combined com
Slide 6: Post Merger Leadership Team
Post Merger Leadership Team Chen Schor President and CEO Stewart Abbot, PhD Chief Scientific and Operating Officer Carrie Krehlik Chief Human Resource Officer Lloyd Klickstein, MD, PhD Chief Innovation Officer Francesco Galimi, MD, PhD Chief Medical Officer
Slide 7: Adicet Strategic Priorities
Adicet Strategic Priorities* *Additional guidance provided after deal close File IND for ADI-001 CD20 gamma-delta CAR-T Initiate Phase 1 clinical study in non-Hodgkin’s lymphoma File IND for ADI-002 GPC3 gamma-delta CAR-T Initiate Phase 1 in hepatocellular carcinoma Expand pipeline in oncology and o
Slide 8: About Adicet Bio
About Adicet Bio Founded in 2015 with $44M Series A financing Completed $80M Series B financing in September 2019 Developing off-the-shelf, engineered allogeneic γδ T cell therapy for oncology indications and other diseases cGMP-compliant manufacturing from healthy donors Proprietary intracellular t
Slide 9: Building a Broad Pipeline of First in Class γδ CAR T Cell Therapy
Building a Broad Pipeline of First in Class γδ CAR T Cell Therapy Abbreviations: HCC: HepatoCellular Carcinoma NH: Non-Hodgkin’s Program Target Indication Discovery Preclinical IND Phase 1 Phase 2 ADI-001 CD20 NH Lymphoma ADI-002 GPC3 HCC ADI-00x Undisclosed Solid Tumors ADI-00x Multiple Solid and H
Slide 10: CAR-T Cell Therapy Journey
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAR-T Cell Therapy Journey 2015 Adicet Bio Founded ~2017 Yescarta approved by US FDA for r/r DLBCL 2012 U. Penn CART19 assets acquired by Novartis 2017 Kite Pharma acquired for $11.9B 2013 Juno Therapeutics founded 2009 Kite Pharm
Slide 11: Engineered γδ T Cells Expected to Solve Key Challenges of Current Cellular Therapies
Engineered γδ T Cells Expected to Solve Key Challenges of Current Cellular Therapies Ideal Cell Therapy High efficacy- ORR/OS Target solid tumors Improved safety Available on demand Significantly lower cost of manufacturing Allogeneic CAR γδ T: Innate and adaptive immunity imparted by TCR and NK rec
Slide 12: Improving Cancer Immunotherapy
Improving Cancer Immunotherapy Presence of γδ T Cells Observed to Strongly Correlate with Positive Clinical Outcomes Meraviglia et al. 2017 Improved Disease Free Progression Colorectal Cancer γδ T cell hi γδ T cell lo γδ T cell lo / IFNγ lo Pan-Cancer: Improved Overall Prognosis Gentles et al. 2015
Slide 13: Differentiation From Other Allogeneic CAR-T
Differentiation From Other Allogeneic CAR-T Ideal Allogeneic CAR-T Therapy Attributes Allogeneic CAR αβ T Cells Allogeneic CART γδ T Cells Potency Recognize and bind tumor Predominantly CAR-mediated CAR and Multiple innate receptors Effectively kill tumor Predominantly CAR-CD8 αβ T subset All Vδ1 T
Slide 14: Large-Scale Manufacture of γδ T Cells
Large-Scale Manufacture of γδ T Cells Simplify for Robustness, Partner for Capability and Capacity Leukopheresis from a qualified donor Activate desired subsets of γδ T cells Engineer γδ T cells with CARs Expand ICP Cell Bank of final “Off the Shelf” ICP Treatment of multiple patients Production Pro
Slide 15: Adicet's Platform Advantages
Adicet’s Platform Advantages Adicet is developing a rich pipeline of near-clinical γδ T cell therapy assets γδ T cells represent a highly active cellular immunotherapy platform γδ T cells represent a universal, off-the-shelf approach to cancer treatment Adicet’s approach is highly differentiated fro
Slide 16: ADI-001: Allogeneic (CD20-CAR-γδ T Cell)
ADI-001: Allogeneic (CD20-CAR-γδ T Cell)
Slide 17: CD20 CAR γδ T Cells Effectively Control Aggressive Lymphoma Tumors in Mice
CD20 CAR γδ T Cells Effectively Control Aggressive Lymphoma Tumors in Mice† Untreated animals succumb to highly aggressive tumors within 3 weeks 2nd generation (employing two co-stimulation domains) CD20 CAR γδ T cells effectively control multiple disseminated (iv) and localized (sc) tumors γδ T cel
Slide 18: CD20 γδ CAR-T Cells Effectively Control Repeat Lymphoma Challenges
CD20 γδ CAR-T Cells Effectively Control Repeat Lymphoma Challenges Repeat tumor challenge is one of the most stringent tests of anti-tumor activity CD20 CAR γδ T cell treatment initiated* when tumor volume ≥ 200mm3 Excellent tumor control in all animals at day 55 Secondary tumor challenge at day 60
Slide 19: CD20 CAR γδ T Cells Proliferate in Response to Activation in Tumors
CD20 CAR γδ T Cells Proliferate in Response to Activation in Tumors Substantial and specific target-mediated proliferation of CD20 CAR γδ T cells in localized lymphoma tumors at 6 days post treatment † Blood Spleen Liver Bone marrow Tumor Cell Number T cell Proliferation Day 2 Post-treatment CAR-T γ
Slide 20: Absence of GvHD with CD20 CAR γδ T Cells
Intravenous Raji Tumor in SRG-15 Mice† Absence of GvHD with CD20 CAR γδ T Cells No GvHD observed in mice treated with γδ T cells γδ T cells not expected to induce GvHD in clinical study No gene editing required to overcome GvHD with γδ T cells αβ CAR-T cell group succumbed to GvHD αβ CART cells CAR
Slide 21: Clinical Development of ADI-001
Clinical Development of ADI-001 Phase 1 study design NHL patients relapsing from 2 or more prior lines of treatment ~3 cohorts for dose escalation/safety Up to 50 patients at the selected dose Single treatment with ADI-001 Option for retreatment in select patients Pivotal study likely in DLBCL and/o
Slide 22: ADI-001 Status
ADI-001 Status Pre-IND meeting completed IND application enabling activities in process ADI-001 IND application preparation in process Proposed ADI-001 clinical trial design well received by key centers and KOLs Preparations for ADI-001 Phase 1 Clinical study underway
Slide 23: Additional Pipeline in Solid Tumors: ADI-002
Additional Pipeline in Solid Tumors: ADI-002
Slide 24: CAR γδ T-Cell: Solving the Challenge of Solid Tumors
CAR γδ T-Cell: Solving the Challenge of Solid Tumors Solid Tumor Challenge Adicet CAR γδ T Cell Solution Autologous cell exhaustion / dysfunction Healthy-donor derived product CMV-negative donors preserve Vδ1 proliferative capacity Potential for >30 population doublings ex vivo / in vivo Specific tu
Slide 25: ADI-002: GPC3 Expression in Solid Tumors
ADI-002: GPC3 Expression in Solid Tumors Baumhoer et al., Am J Clin Pathol 2008;129:899-906 Ho et al., PLoS ONE 2012; 7: e37159 IHC Detection of GPC3 in human HCC vs normal liver GPC3 is highly expressed on a broad range of solid tumors, with limited expression levels on normal tissues Adicet Bio Co
Slide 26: Dose Dependent Anti-Tumor Effect of Vδ1 CAR-T Cells with GPC3-Targeting sIL15
Dose Dependent Anti-Tumor Effect of Vδ1 CAR-T Cells with GPC3-Targeting sIL15 CAR γδ1 T Cells in Liver Cancer Model † GPC3-targeting chimeric antigen receptor construct also encodes secretion of IL15 Single dose CAR γδ T cell treatment was initiated* when tumor volumes reached ~200mm3 Excellent CAR
Slide 27: Adicet's Advantage of ADI-002 in HCC
Adicet’s Advantage of ADI-002 in HCC Potential to address low target tumor densities CAR-dependent and CAR-independent tumor targeting Optimizing γδ T cells to overcome tumor microenvironment-mediated immunosuppression Enhancing persistence of CAR-γδ T cells Favorable preclinical results Opportuniti
Slide 28: TCR-L Platform: Intracellular Solid Tumor Targets
TCR-L Platform: Intracellular Solid Tumor Targets
Slide 29: TCR-L Platform: CAR-T Using Intracellular Solid Tumor Targets
TCR-L Platform: CAR-T Using Intracellular Solid Tumor Targets Challenge Lack of disease-specific cell surface targets in solid tumors (80% of proteins are intracellular) Solution Ability to target disease-specific intracellular proteins via peptide MHC complexes highly expands the target pool Unlike
Slide 30: Deal Rationale
Deal Rationale Potential Best-In-Class Allogeneic CAR-T Cell Therapy with Significant Commercial Opportunity First Mover Advantage in the Field of Gamma-Delta CAR-T Cell Therapy Differentiated and Innovative Gamma Delta CAR-T Cell Pipeline Proprietary Intracellular Tumor-Selective Targeting Platform
Slide 31: RTB101: Potent Target of rapamycin complex (TORC1) inhibitor
RTB101: Potent Target of rapamycin complex 1 (TORC1) inhibitor
Slide 32: RTB101
RTB101 Expect to continue the development of RTB101 for a COVID-19 related indication, with clinical data expected by Q1 2021. The terms of the merger agreement contemplate that a contingent value right (a “CVR”) will be distributed to resTORbio stockholders as of the effective time of the merger, e